Revance Therapeutics, Inc. (RVNC) Now Covered by Analysts at Mizuho
Mizuho started coverage on shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) in a research note issued to investors on Thursday. The firm issued a buy rating and a $37.00 price target on the biopharmaceutical company’s stock.
A number of other research firms have also issued reports on RVNC. Zacks Investment Research upgraded shares of Revance Therapeutics from a hold rating to a buy rating and set a $26.00 target price on the stock in a report on Wednesday, August 30th. BidaskClub upgraded shares of Revance Therapeutics from a sell rating to a hold rating in a report on Friday, August 18th. Piper Jaffray Companies set a $28.00 target price on shares of Revance Therapeutics and gave the stock a buy rating in a report on Wednesday, July 26th. Cantor Fitzgerald reiterated a buy rating and set a $50.00 target price on shares of Revance Therapeutics in a report on Tuesday, September 26th. Finally, JMP Securities started coverage on shares of Revance Therapeutics in a report on Tuesday, August 22nd. They set an outperform rating and a $34.00 target price on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Revance Therapeutics has a consensus rating of Buy and an average price target of $35.50.
Revance Therapeutics (RVNC) traded up $0.45 during trading on Thursday, reaching $25.95. 679,975 shares of the company’s stock were exchanged, compared to its average volume of 176,782. Revance Therapeutics has a 12 month low of $15.85 and a 12 month high of $28.75.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. Revance Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.64) earnings per share. equities analysts predict that Revance Therapeutics will post -3.73 earnings per share for the current year.
In other news, Director Mark J. Foley acquired 20,000 shares of Revance Therapeutics stock in a transaction dated Tuesday, November 7th. The shares were acquired at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now owns 6,000 shares of the company’s stock, valued at $161,760. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total transaction of $179,208.00. Following the completion of the sale, the chief executive officer now owns 148,450 shares in the company, valued at $3,500,451. The disclosure for this sale can be found here. Insiders sold a total of 59,226 shares of company stock worth $1,464,618 over the last 90 days. Company insiders own 18.86% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in RVNC. Franklin Resources Inc. raised its holdings in shares of Revance Therapeutics by 13.1% in the 2nd quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock valued at $89,106,000 after purchasing an additional 391,638 shares in the last quarter. Jennison Associates LLC acquired a new stake in shares of Revance Therapeutics in the 2nd quarter valued at $9,990,000. Bank of New York Mellon Corp grew its position in shares of Revance Therapeutics by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock valued at $54,901,000 after buying an additional 261,764 shares during the last quarter. FMR LLC grew its position in shares of Revance Therapeutics by 216.9% in the 1st quarter. FMR LLC now owns 316,900 shares of the biopharmaceutical company’s stock valued at $6,592,000 after buying an additional 216,900 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Revance Therapeutics by 4.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after buying an additional 166,759 shares during the last quarter. Institutional investors and hedge funds own 88.70% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.